Log in to save to my catalogue

Goserelin for Ovarian Protection during Breast-Cancer Adjuvant Chemotherapy

Goserelin for Ovarian Protection during Breast-Cancer Adjuvant Chemotherapy

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4405231

Goserelin for Ovarian Protection during Breast-Cancer Adjuvant Chemotherapy

About this item

Full title

Goserelin for Ovarian Protection during Breast-Cancer Adjuvant Chemotherapy

Publisher

United States: Massachusetts Medical Society

Journal title

The New England journal of medicine, 2015-03, Vol.372 (10), p.923-932

Language

English

Formats

Publication information

Publisher

United States: Massachusetts Medical Society

More information

Scope and Contents

Contents

Women with hormone-receptor–negative breast cancer who received goserelin with adjuvant chemotherapy had less amenorrhea and better fertility at 2 years after treatment, and better rates of disease-free and overall survival, than did those who received chemotherapy alone.
Early ovarian failure is an important and potentially devastating long-ter...

Alternative Titles

Full title

Goserelin for Ovarian Protection during Breast-Cancer Adjuvant Chemotherapy

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4405231

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4405231

Other Identifiers

ISSN

0028-4793

E-ISSN

1533-4406

DOI

10.1056/NEJMoa1413204

How to access this item